Burden of a multiple sclerosis relapse: The patients perspective

Patient

Volumn 5, Issue 1, 2012, Pages 57-69

  Oleen Burkey, Merrikay K ^a   Castelli Haley, Jane ^a   Lage, Maureen J ^b   Johnson, Kenneth P ^c  

^a Medical Affairs   (United States)

^b HealthMetrics Outcomes Research   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

Author keywords

Cost of illness; Multiple sclerosis; Quality of life.

Indexed keywords

BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ADULT; AMBULATORY CARE; ARTICLE; ATTITUDE TO ILLNESS; COST OF ILLNESS; DISABILITY; DISEASE SEVERITY; DRUG COST; FEMALE; FUNCTIONAL STATUS; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; INTERNET; LEISURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PATIENT ATTITUDE; PRIORITY JOURNAL; PRODUCTIVITY; QUALITY ADJUSTED LIFE YEAR; RELAPSE; SELF REPORT; WORK CAPACITY;

ADULT; COST OF ILLNESS; CROSS-SECTIONAL STUDIES; EFFICIENCY; FEMALE; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; SOCIOECONOMIC FACTORS;

EID: 84856356607     PISSN: 11781653     EISSN: 11781661     Source Type: Journal    
DOI: 10.2165/11592160-000000000-00000     Document Type: Article

References (51)

1. National Multiple Sclerosis Society. Epidemiology of MS [online]. Available from URL: http://www.nationalmsso ciety.org/about-multiple-sclerosis/ what-we-know-about-ms/who-gets-ms/epidemiology-of-ms/index.aspx [Accessed 2010 Aug 5]
2. Minden SL, Frankel D, Hadden L, et al. The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics. Mult Scler 2006 Feb; 12 (1): 24-38 (Pubitemid 43169235)
3. Jacobs LD, Wende KE, Brownscheidle CM, et al. A profile of multiple sclerosis: the New York State Multiple Sclerosis Consortium. Mult Scler 1999 Oct; 5 (5): 369-76 (Pubitemid 29505053)
4. Ollendorf DA, Jilinskaia E, Oleen-Burkey M. Clinical and economic impact of glatiramer acetate versus beta interferon therapy among patients with multiple sclerosis in a managed care population. J Manag Care Pharm 2002 Nov- Dec; 8 (6): 469-76
5. Prescott JD, Factor S, Pill M, et al. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm 2007 Jan-Feb; 13 (1): 44-52 (Pubitemid 46824250)
6. Ivanova JI, Birnbaum HG, Samuels S, et al. The cost of disability and medically related absenteeism among employees with multiple sclerosis in the US. Pharmacoeconomics 2009; 27 (8): 681-91
7. Lage MJ, Castelli-Haley J, Oleen-Burkey M.A. Effect of immunomodulatory therapy and other factors on employment loss time in multiple sclerosis. Work 2006; 27 (2): 143-51 (Pubitemid 44355728)
8. Whetten-Goldstein K, Sloan FA, Goldstein LB, et al. A comprehensive assessment of the cost of multiple sclerosis in the United States. Mult Scler 1998 Oct; 4 (5): 419-25 (Pubitemid 28515352)
9. Kobelt G, Berg J, Atherly D, et al. Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States. Neurology 2006 Jun 13; 66 (11): 1696-702 (Pubitemid 43964625)
10. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, 2: predictive value of the early clinical course. Brain 1989 Dec; 112 (Pt 6): 1419-28 (Pubitemid 20024212)
11. Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study, 1: clinical course and disability. Brain 1989 Feb; 112 (Pt 1): 133-46 (Pubitemid 19056478)
12. Thrower BW. Relapse management in multiple sclerosis. Neurologist 2009 Jan; 15 (1): 1-5
13. Halper J. The psychosocial effect of multiple sclerosis: the impact of relapses. J Neurol Sci 2007 May 15; 256 Suppl. 1: S34-8 (Pubitemid 46560634)
14. Morrow TJ. The costs and consequences of multiple sclerosis relapses: a managed care perspective. J Neurol Sci 2007 May 15; 256 Suppl. 1: S39-44 (Pubitemid 46560638)
15. Weis R, Stamm K, Smith C, et al. Communities of care and caring: the case of MSWatC.H.com. J Health Psychol 2003; 8: 135-48 (Pubitemid 36142822)
16. Henriksson F, Fredrikson S, Masterman T, et al. Costs, quality of life and disease severity in multiple sclerosis: a crosssectional study in Sweden. Eur J Neurol 2001 Jan; 8 (1): 27-35 (Pubitemid 32154571)
17. Kobelt G, Lindgren P, Parkin D, et al. Costs and quality of life of in multiple sclerosis: a cross sectional observational study in the United Kingdom. SSE/EFI working paper series in economics and finance no. 398. Stockholm: Stockholm School of Economics, 2000
18. Kobelt G, Lindgren P, Smala A, et al. Costs and quality of life in multiple sclerosis: a cross sectional observation study in Germany. Eur J Health Econ 2001; 2: 60-8 (Pubitemid 33014731)
19. Reilly M, Tanner A, Meltzer E. Work, classroom and activity impairment instruments: validation studies in allergic rhinitis. Clin Drug Invest 1996; 11: 278-88
20. Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics 1993 Nov; 4 (5): 353-65
21. US Bureau of Labor. Occupational employment statistics, 2008 [online]. Available from URL: http://www.bls.gov/OES [Accessed 2010 Jun 23]
22. Goodin DS. A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler 1998 Oct; 4 (5): 444-51 (Pubitemid 28515356)
23. Goodin DS. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler 1999 Apr; 5 (2): 78-88 (Pubitemid 29186824)
24. EuroQol: a new facility for the measurement of healthrelated quality of life. The EuroQol Group. Health Policy 1990 Dec; 16 (3): 199-208
25. Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001 Jul; 33 (5): 337-43 (Pubitemid 32675374)
26. Kind P. The EuroQoL instrument: an index of healthrelated quality of life. In: Spilker B, editor. Quality of life and pharmacoeconomics in clinical trials. Philadelphia (PA): Lippincott-Raven Publishers, 1996: 191-201
27. Dolan P, Gudex C, Kind P, et al. Social tariff for the Euro- QoL: results from a UK general population survey. York: Centre for Health Economics, University of York, 1995
28. Johannesson M. At what coronary risk level is it costeffective to initiate cholesterol lowering drug treatment in primary prevention? Eur Heart J 2001 Jun; 22 (11): 919-25 (Pubitemid 32625214)
29. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of patients with multiple sclerosis in Europe. J Neurol Neurosurg Psychiatry 2006 Aug; 77 (8): 918-26 (Pubitemid 44174075)
30. McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008; 26 (10): 847-60
31. Taylor B, McDonald E, Fantino B, et al. The cost of multiple sclerosis in Australia. J Clin Neurosci 2007 Jun; 14 (6): 532-9 (Pubitemid 46553791)
32. Coyle PK. Gender issues. Neurol Clin 2005 Feb; 23 (1): 39-60 (Pubitemid 40126914)
33. O'Brien JA, Ward AJ, Patrick AR, et al. Cost of managing an episode of relapse in multiple sclerosis in the United States. BMC Health Serv Res 2003 Sep 2; 3 (1): 17
34. Grima DT, Torrance GW, Francis G, et al. Cost and health related quality of life consequences of multiple sclerosis. Mult Scler 2000 Apr; 6 (2): 91-8 (Pubitemid 30218902)
35. Rivera-Navarro J, Benito-Leon J, Oreja-Guevara C, et al. Burden and health-related quality of life of Spanish caregivers of persons with multiple sclerosis. Mult Scler 2009 Nov; 15 (11): 1347-55
36. Rivera-Navarro J, Morales-Gonzalez JM, Benito-Leon J. Informal caregiving in multiple sclerosis patients: data from the Madrid Demyelinating Disease Group Study. Disabil Rehabil 2003 Sep 16; 25 (18): 1057-64 (Pubitemid 37168686)
37. Kobelt G, Berg J, Lindgren P, et al. Costs and quality of life of multiple sclerosis in the United Kingdom. Eur J Health Econ 2006 Sep; 7 Suppl. 2: S96-104
38. Kalb R. The emotional and psychological impact of multiple sclerosis relapses. J Neurol Sci 2007 May 15; 256 Suppl. 1: S29-33 (Pubitemid 46560636)
39. Orme M, Kerrigan J, Tyas D, et al. The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value Health 2007 Jan-Feb; 10 (1): 54-60 (Pubitemid 46161095)
40. Patwardhan MB, Matchar DB, Samsa GP, et al. Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005 Apr; 11 (2): 232-9 (Pubitemid 40403265)
41. Lublin FD, Baier M, Cutter G. Effect of relapses on development of residual deficit in multiple sclerosis. Neurology 2003 Dec 9; 61 (11): 1528-32 (Pubitemid 37505574)
42. Hirst C, Ingram G, Pearson O, et al. Contribution of relapses to disability in multiple sclerosis. J Neurol 2008 Feb; 255 (2): 280-7
43. Confavreux C, Vukusic S, Adeleine P. Early clinical predictors and progression of irreversible disability in multiple sclerosis: an amnesic process. Brain 2003 Apr; 126 (Pt 4): 770-82 (Pubitemid 36372978)
44. Tremlett H, Yousefi M, Devonshire V, et al. Impact of multiple sclerosis relapses on progression diminishes with time. Neurology 2009 Nov 17; 73 (20): 1616-23
45. O'Connor P, Filippi M, Arnason B, et al. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol 2009 Oct; 8 (10): 889-97
46. Mikol DD, Barkhof F, Chang P, et al. Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. Lancet Neurol 2008 Oct; 7 (10): 903-14
47. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsingremitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995 Jul; 45 (7): 1268-76
48. Khan OA, Tselis AC, Kamholz JA, et al. A prospective, open-label treatment trial to compare the effect of IFNbeta-1a (Avonex), IFNbeta-1b (Betaseron), and glatiramer acetate (Copaxone) on the relapse rate in relapsing-remitting multiple sclerosis: results after 18 months of therapy. Mult Scler 2001 Dec; 7 (6): 349-53 (Pubitemid 33138343)
49. Haas J, Firzlaff M. Twenty-four-month comparison of immunomodulatory treatments-a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone). Eur J Neurol 2005 Jun; 12 (6): 425-31 (Pubitemid 40768660)
50. The IFNB Multiple Sclerosis Study Group. Interferon beta- 1b is effective in relapsing-remitting multiple sclerosis, I: clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993 Apr; 43 (4): 655-61
51. Minden S, Hoaglin D, Jureidini S, et al. Disease-modifying agents in the Sonya Slifka Longitudinal Multiple Sclerosis Study. Mult Scler 2008 Jun; 14 (5): 640-55 (Pubitemid 351954407)